Skip to main content

ARS Pharmaceuticals, Inc 8-K, filed Nov 5, 2026

ARS Pharmaceuticals, Inc. (SPRY)

8-K 2026-11-05 For: 2026-11-05
View Original
Added on November 05, 2026

About this 8-K

ARS Pharmaceuticals, Inc filed this 8-K on November 5, 2026.

ARS Pharmaceuticals reported third-quarter revenue of $37.7 million, up from $32.5 million, while operating expenses fell to $71.9 million and net loss narrowed to $35.6 million from $51.2 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits